Lansen Pharmaceutical Holdings Balance Sheet Health
Financial Health criteria checks 5/6
Lansen Pharmaceutical Holdings has a total shareholder equity of $123.6M and total debt of $17.6M, which brings its debt-to-equity ratio to 14.2%. Its total assets and total liabilities are $175.0M and $51.3M respectively. Lansen Pharmaceutical Holdings's EBIT is $12.4M making its interest coverage ratio -35.1. It has cash and short-term investments of $46.4M.
Key information
14.2%
Debt to equity ratio
US$17.58m
Debt
| Interest coverage ratio | -35.1x |
| Cash | US$46.39m |
| Equity | US$123.64m |
| Total liabilities | US$51.34m |
| Total assets | US$174.98m |
Recent financial health updates
Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?
Sep 18
Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?
Mar 27Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet
Sep 27Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Dec 06Recent updates
Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?
Sep 18Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?
Mar 27Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet
Sep 27Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Dec 06Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Sep 04We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings
Dec 28
Financial Position Analysis
Short Term Liabilities: 503's short term assets ($125.7M) exceed its short term liabilities ($49.4M).
Long Term Liabilities: 503's short term assets ($125.7M) exceed its long term liabilities ($2.0M).
Debt to Equity History and Analysis
Debt Level: 503 has more cash than its total debt.
Reducing Debt: 503's debt to equity ratio has reduced from 88.6% to 14.2% over the past 5 years.
Debt Coverage: 503's debt is not well covered by operating cash flow (14.3%).
Interest Coverage: 503 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/20 21:45 |
| End of Day Share Price | 2023/11/28 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lansen Pharmaceutical Holdings Limited is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Ming Kong | DBS Vickers Research |
| Stephen Wang | KGI Securities Co. Ltd. |
| Hongbo Lu | Piper Sandler Companies |